AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CGTX
  4. [Form 4] Cognition Therapeutics, Inc. Insider Trading Activity

[Form 4] Cognition Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cognition Therapeutics director Jack A. Khattar received a grant of 34,000 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Khattar's direct ownership increased to 48,500 shares.

Key details of the RSU grant:

  • The RSUs were granted at $0.00 cost basis
  • Vesting occurs at the earlier of June 18, 2026 or the next annual stockholder meeting
  • Vesting is contingent on continuous service as director
  • Each RSU converts to one share of common stock upon settlement

This Form 4 filing, signed by attorney-in-fact John Brendan Doyle, represents a standard equity compensation grant for non-employee directors, aligning the director's interests with shareholders through longer-term equity ownership.

Jack A. Khattar, direttore di Cognition Therapeutics, ha ricevuto il 18 giugno 2025 una concessione di 34.000 unit脿 azionarie vincolate (RSU). Dopo questa operazione, la propriet脿 diretta di Khattar 猫 aumentata a 48.500 azioni.

Dettagli principali della concessione di RSU:

  • Le RSU sono state concesse con un costo base di $0,00
  • Il vesting avviene alla prima tra il 18 giugno 2026 o la successiva assemblea annuale degli azionisti
  • Il vesting 猫 subordinato alla continuit脿 del servizio come direttore
  • Ogni RSU si converte in un'azione ordinaria al momento della liquidazione

Questo deposito del Modulo 4, firmato dall鈥檃vvocato-in-fatto John Brendan Doyle, rappresenta una tipica concessione di compensi azionari per direttori non dipendenti, allineando gli interessi del direttore con quelli degli azionisti tramite una partecipazione azionaria a lungo termine.

Jack A. Khattar, director de Cognition Therapeutics, recibi贸 una concesi贸n de 34,000 unidades restringidas de acciones (RSU) el 18 de junio de 2025. Tras esta transacci贸n, la propiedad directa de Khattar aument贸 a 48,500 acciones.

Detalles clave de la concesi贸n de RSU:

  • Las RSU se otorgaron con un costo base de $0.00
  • La adquisici贸n ocurre a la primera de las siguientes fechas: 18 de junio de 2026 o la pr贸xima junta anual de accionistas
  • La adquisici贸n est谩 condicionada a la continuidad del servicio como director
  • Cada RSU se convierte en una acci贸n com煤n al momento del pago

Esta presentaci贸n del Formulario 4, firmada por el apoderado John Brendan Doyle, representa una concesi贸n est谩ndar de compensaci贸n en acciones para directores no empleados, alineando los intereses del director con los de los accionistas mediante la propiedad accionaria a largo plazo.

Cognition Therapeutics鞚� 鞚挫偓 Jack A. Khattar電� 2025雲� 6鞗� 18鞚检棎 34,000臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 Khattar鞚� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 48,500欤�搿� 歃濌皜頄堨姷雼堧嫟.

RSU 攵�鞐潣 欤检殧 雮挫毄:

  • RSU電� $0.00鞚� 旆摑 鞗愱皜搿� 攵�鞐惃
  • 氩犾姢韺呾潃 2026雲� 6鞗� 18鞚� 霕愲姅 雼れ潓 鞐半 欤检＜齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 氚滌儩
  • 氩犾姢韺呾潃 鞚挫偓搿滌劀鞚� 歆�靻嶌爜鞚� 攴茧臧� 臁瓣贝鞛�
  • 臧� RSU電� 鞝曥偘 鞁� 氤错喌欤� 1欤茧 鞝勴櫂霅�

鞚� Form 4 鞝滌稖靹滊姅 氩曥爼雽�毽澑 John Brendan Doyle臧� 靹滊獏頃� 瓴冹溂搿�, 牍勳鞗� 鞚挫偓鞐� 雽�頃� 響滌 欤检嫕 氤挫儊 攵�鞐ゼ 雮橅儉雮措┌, 鞛リ赴 欤检嫕 氤挫湢毳� 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偆電� 氇╈爜鞛呺媹雼�.

Jack A. Khattar, administrateur de Cognition Therapeutics, a re莽u une attribution de 34 000 unit茅s d鈥檃ctions restreintes (RSU) le 18 juin 2025. Suite 脿 cette op茅ration, la d茅tention directe de Khattar a augment茅 pour atteindre 48 500 actions.

Points cl茅s de l鈥檃ttribution des RSU :

  • Les RSU ont 茅t茅 attribu茅es 脿 un co没t de base de 0,00 $
  • L鈥檃cquisition intervient au plus t么t entre le 18 juin 2026 ou la prochaine assembl茅e g茅n茅rale annuelle des actionnaires
  • L鈥檃cquisition est conditionn茅e 脿 la continuit茅 du service en tant qu鈥檃dministrateur
  • Chaque RSU se convertit en une action ordinaire lors du r猫glement

Ce d茅p么t du formulaire 4, sign茅 par le mandataire John Brendan Doyle, repr茅sente une attribution standard de r茅mun茅ration en actions pour les administrateurs non salari茅s, alignant les int茅r锚ts de l鈥檃dministrateur sur ceux des actionnaires via une d茅tention d鈥檃ctions 脿 long terme.

Jack A. Khattar, Direktor von Cognition Therapeutics, erhielt am 18. Juni 2025 einen Zuschuss von 34.000 Restricted Stock Units (RSUs). Nach dieser Transaktion erh枚hte sich Khattars direkte Beteiligung auf 48.500 Aktien.

Wichtige Details zum RSU-Zuschuss:

  • Die RSUs wurden zu einem Kostenbasis von 0,00 $ gew盲hrt
  • Die Vesting erfolgt zum fr眉heren Zeitpunkt von 18. Juni 2026 oder der n盲chsten j盲hrlichen Hauptversammlung
  • Die Vesting ist an die fortlaufende T盲tigkeit als Direktor gebunden
  • Jede RSU wird bei Auszahlung in eine Stammaktie umgewandelt

Diese Form 4 Einreichung, unterzeichnet vom Bevollm盲chtigten John Brendan Doyle, stellt eine 眉bliche Aktienverg眉tung f眉r nicht angestellte Direktoren dar und sorgt daf眉r, dass die Interessen des Direktors durch langfristigen Aktienbesitz mit denen der Aktion盲re in Einklang stehen.

Positive
  • None.
Negative
  • None.

Jack A. Khattar, direttore di Cognition Therapeutics, ha ricevuto il 18 giugno 2025 una concessione di 34.000 unit脿 azionarie vincolate (RSU). Dopo questa operazione, la propriet脿 diretta di Khattar 猫 aumentata a 48.500 azioni.

Dettagli principali della concessione di RSU:

  • Le RSU sono state concesse con un costo base di $0,00
  • Il vesting avviene alla prima tra il 18 giugno 2026 o la successiva assemblea annuale degli azionisti
  • Il vesting 猫 subordinato alla continuit脿 del servizio come direttore
  • Ogni RSU si converte in un'azione ordinaria al momento della liquidazione

Questo deposito del Modulo 4, firmato dall鈥檃vvocato-in-fatto John Brendan Doyle, rappresenta una tipica concessione di compensi azionari per direttori non dipendenti, allineando gli interessi del direttore con quelli degli azionisti tramite una partecipazione azionaria a lungo termine.

Jack A. Khattar, director de Cognition Therapeutics, recibi贸 una concesi贸n de 34,000 unidades restringidas de acciones (RSU) el 18 de junio de 2025. Tras esta transacci贸n, la propiedad directa de Khattar aument贸 a 48,500 acciones.

Detalles clave de la concesi贸n de RSU:

  • Las RSU se otorgaron con un costo base de $0.00
  • La adquisici贸n ocurre a la primera de las siguientes fechas: 18 de junio de 2026 o la pr贸xima junta anual de accionistas
  • La adquisici贸n est谩 condicionada a la continuidad del servicio como director
  • Cada RSU se convierte en una acci贸n com煤n al momento del pago

Esta presentaci贸n del Formulario 4, firmada por el apoderado John Brendan Doyle, representa una concesi贸n est谩ndar de compensaci贸n en acciones para directores no empleados, alineando los intereses del director con los de los accionistas mediante la propiedad accionaria a largo plazo.

Cognition Therapeutics鞚� 鞚挫偓 Jack A. Khattar電� 2025雲� 6鞗� 18鞚检棎 34,000臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 Khattar鞚� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 48,500欤�搿� 歃濌皜頄堨姷雼堧嫟.

RSU 攵�鞐潣 欤检殧 雮挫毄:

  • RSU電� $0.00鞚� 旆摑 鞗愱皜搿� 攵�鞐惃
  • 氩犾姢韺呾潃 2026雲� 6鞗� 18鞚� 霕愲姅 雼れ潓 鞐半 欤检＜齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 氚滌儩
  • 氩犾姢韺呾潃 鞚挫偓搿滌劀鞚� 歆�靻嶌爜鞚� 攴茧臧� 臁瓣贝鞛�
  • 臧� RSU電� 鞝曥偘 鞁� 氤错喌欤� 1欤茧 鞝勴櫂霅�

鞚� Form 4 鞝滌稖靹滊姅 氩曥爼雽�毽澑 John Brendan Doyle臧� 靹滊獏頃� 瓴冹溂搿�, 牍勳鞗� 鞚挫偓鞐� 雽�頃� 響滌 欤检嫕 氤挫儊 攵�鞐ゼ 雮橅儉雮措┌, 鞛リ赴 欤检嫕 氤挫湢毳� 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偆電� 氇╈爜鞛呺媹雼�.

Jack A. Khattar, administrateur de Cognition Therapeutics, a re莽u une attribution de 34 000 unit茅s d鈥檃ctions restreintes (RSU) le 18 juin 2025. Suite 脿 cette op茅ration, la d茅tention directe de Khattar a augment茅 pour atteindre 48 500 actions.

Points cl茅s de l鈥檃ttribution des RSU :

  • Les RSU ont 茅t茅 attribu茅es 脿 un co没t de base de 0,00 $
  • L鈥檃cquisition intervient au plus t么t entre le 18 juin 2026 ou la prochaine assembl茅e g茅n茅rale annuelle des actionnaires
  • L鈥檃cquisition est conditionn茅e 脿 la continuit茅 du service en tant qu鈥檃dministrateur
  • Chaque RSU se convertit en une action ordinaire lors du r猫glement

Ce d茅p么t du formulaire 4, sign茅 par le mandataire John Brendan Doyle, repr茅sente une attribution standard de r茅mun茅ration en actions pour les administrateurs non salari茅s, alignant les int茅r锚ts de l鈥檃dministrateur sur ceux des actionnaires via une d茅tention d鈥檃ctions 脿 long terme.

Jack A. Khattar, Direktor von Cognition Therapeutics, erhielt am 18. Juni 2025 einen Zuschuss von 34.000 Restricted Stock Units (RSUs). Nach dieser Transaktion erh枚hte sich Khattars direkte Beteiligung auf 48.500 Aktien.

Wichtige Details zum RSU-Zuschuss:

  • Die RSUs wurden zu einem Kostenbasis von 0,00 $ gew盲hrt
  • Die Vesting erfolgt zum fr眉heren Zeitpunkt von 18. Juni 2026 oder der n盲chsten j盲hrlichen Hauptversammlung
  • Die Vesting ist an die fortlaufende T盲tigkeit als Direktor gebunden
  • Jede RSU wird bei Auszahlung in eine Stammaktie umgewandelt

Diese Form 4 Einreichung, unterzeichnet vom Bevollm盲chtigten John Brendan Doyle, stellt eine 眉bliche Aktienverg眉tung f眉r nicht angestellte Direktoren dar und sorgt daf眉r, dass die Interessen des Direktors durch langfristigen Aktienbesitz mit denen der Aktion盲re in Einklang stehen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Khattar Jack A.
(Last) (First) (Middle)
C/O COGNITION THERAPEUTICS, INC.
2500 WESTCHESTER AVE
(Street)
PURCHASE NY 10577
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
COGNITION THERAPEUTICS INC [ CGTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 34,000(1) A $0.00 48,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 18, 2026 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
/s/ John Brendan Doyle, Attorney-in-Fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many CGTX shares did director Jack Khattar acquire on June 18, 2025?

Director Jack Khattar acquired 34,000 shares of CGTX in the form of Restricted Stock Units (RSUs) on June 18, 2025. These RSUs were granted at a price of $0.00 per share.

When do Jack Khattar's CGTX RSUs vest?

The RSUs vest in full on the earlier of two dates: (1) June 18, 2026, or (2) the date of Cognition Therapeutics' next annual meeting of stockholders. The vesting is subject to Khattar's continuous service as a director through the applicable vesting date.

What is Jack Khattar's total CGTX share ownership after the June 2025 RSU grant?

Following the RSU grant transaction, Jack Khattar beneficially owns 48,500 shares of Cognition Therapeutics (CGTX) stock directly. This includes both previously held shares and the new RSU grant.

What position does Jack Khattar hold at CGTX?

According to the Form 4 filing, Jack Khattar serves as a Director on the board of Cognition Therapeutics (CGTX). The filing indicates he is not an officer or 10% owner of the company.
Stock CGTX logo
COGNITION THERAPEUTICS INC

NASDAQ:CGTX

CGTX Rankings

#4052 Ranked by Market Cap
N/A Ranked by Dividends

CGTX Latest News

Aug 26, 2025
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug 12, 2025
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer鈥檚 Disease
Aug 7, 2025
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
Jul 29, 2025
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer鈥檚 Disease
Jul 21, 2025
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine鈥檚 Protection of Neurons and Synapses in Alzheimer鈥檚 Disease

CGTX Latest SEC Filings

Aug 26, 2025
[8-K] Cognition Therapeutics, Inc. Reports Material Event
Aug 7, 2025
[8-K] Cognition Therapeutics, Inc. Reports Material Event
Jul 31, 2025
[Form 4] Cognition Therapeutics, Inc. Insider Trading Activity
Jul 31, 2025
[Form 4] Cognition Therapeutics, Inc. Insider Trading Activity
Jul 31, 2025
[Form 4] Cognition Therapeutics, Inc. Insider Trading Activity

CGTX Stock Data

233.64M
72.85M
0.85%
15.33%
8.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
PITTSBURGH